GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that is being investigated in the Phase 2 part of an ongoing Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an injectable 5-MeO-DMT product candidate that is in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was founded in 2018 and is based in Dublin, Ireland.
IPO Year: 2021
Exchange: NASDAQ
Website: ghres.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/13/2025 | $19.00 | Buy | Needham |
| 6/4/2025 | $25.00 | Overweight | Cantor Fitzgerald |
| 3/13/2025 | $32.00 | Buy | Guggenheim |
| 3/7/2025 | $31.00 | Outperform | RBC Capital Mkts |
| 2/13/2025 | $14.00 | Overweight | Cantor Fitzgerald |
| 8/16/2022 | $45.00 | Buy | H.C. Wainwright |
| 6/16/2022 | $66.00 | Buy | ROTH Capital |
| 7/20/2021 | Buy | Stifel | |
| 7/20/2021 | $35.00 | Mkt Outperform | JMP Securities |
| 7/20/2021 | Outperform | Cowen & Co. |
Fastest customizable press release news feed in the world
DUBLIN, June 04, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (NASDAQ:GHRS) today announced the publication of the full results from its Phase 2a trial in postpartum depression (PPD) and the acceptance of two oral presentations at the 37th World Congress of Neuropsychopharmacology (CINP 2026). The peer-reviewed article, titled "Inhaled Mebufotenin (GH001) for Adult Patients with Postpartum Depression: A Phase 2a Open-Label Clinical Trial," has been published in The Journal of Clinical Psychiatry (DOI: 10.4088/JCP.25m16284). The article reports the full results from the Phase 2a, single-arm, open-label trial, which enrolled 10 adult women with PPD. Key results: Primary endpoint met: Mean Mont
Phase 2b results in TRD published in JAMA PsychiatryGH001-HV-106 study enrolment completed; doses selected for the global Phase 3 pivotal program of GH001 in TRDGH001-HV-109 US IND-opening study enrolment completedCash, cash equivalents and marketable securities of $267.3 million as of March 31, 2026Net cash proceeds of an additional $111.2 million from underwritten offering received in April 2026 DUBLIN, May 14, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (NASDAQ:GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today reported financial results for the quarter ended March 31, 2026, and
DUBLIN, April 29, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (NASDAQ:GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today announced the pricing of an underwritten offering in the United States of 6,527,779 of its ordinary shares at an offering price of $18.00 per share for total gross proceeds of approximately $117.5 million, before deducting underwriting discounts and commissions and offering expenses. All of the ordinary shares are being offered by GH Research PLC. The offering is expected to close on April 30, 2026, subject to customary closing conditions. The offering was initia
DUBLIN, April 20, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (NASDAQ:GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today issued a statement welcoming the White House Executive Order, signed on April 18, 2026, to accelerate medical treatments for serious mental illness, including innovative psychedelic medical treatments (the Executive Order). The Executive Order directs coordinated federal action to accelerate the development of, and expand patient access to, innovative therapies for serious mental illness. GH Research continues to advance GH001, its proprietary inhaled mebufotenin
Phase 2b results for GH001 in TRD now published and peer-reviewed in JAMA Psychiatry New peer-reviewed article in forthcoming issue of Psychopharmacology Bulletin demonstrates that GH001 efficacy is independent of prior antidepressant treatment failures DUBLIN, March 25, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (NASDAQ:GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today announced two peer-reviewed publications from its Phase 2b clinical program of GH001 in treatment-resistant depression (TRD): the primary trial results in JAMA Psychiatry, and a new analysis demonstrating that eff
Issued on behalf of Cybin D/B/A Helus PharmaUSANewsGroup.com News CommentaryVANCOUVER, BC, March 9, 2026 /CNW/ -- The central nervous system therapeutics sector is approaching a commercial inflection point as multiple candidates advance through late-stage trials and regulatory milestones accumulate1. The Drug Enforcement Administration raised its 2026 production quotas for controlled research compounds by 67%, reflecting expanding clinical trial activity across the therapeutics landscape2. Five companies are working to translate that momentum into approved treatments: Helus Pharma (NASDAQ:HELP), Compass Pathways (NASDAQ:CMPS), AtaiBeckley (NASDAQ:ATAI), Definium Therapeutics (NASDAQ:DFTX), a
Completed Phase 2b trial of GH001 in TRD and presented the full dataset at the 2025 ASCP and ECNP congressesGH001 cleared by FDA for U.S. clinical investigation, enabling U.S. subject enrollmentCash, cash equivalents and marketable securities of $280.7 million as of December 31, 2025 DUBLIN, Ireland, March 05, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (NASDAQ:GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today reported financial results for the year ended December 31, 2025, and provided a business update. Business Update In 2025, the Company completed its Phase 2b trial of GH001
Issued on behalf of Helus PharmaVANCOUVER, BC, Feb. 27, 2026 /CNW/ -- Equity-Insider.com News Commentary -- Psychedelic compounds are edging closer to regulatory approval as pivotal trials in treatment-resistant depression and anxiety advance through late-stage development[1]. The sector is shedding its countercultural reputation as biotech firms reposition serotonergic and psychedelic-derived therapies as mainstream pharmaceutical candidates[2]. Five companies are building the clinical programs to get there: Helus Pharma (NASDAQ:HELP), AtaiBeckley (NASDAQ:ATAI), Definium Therapeutics (NASDAQ:DFTX), GH Research (NASDAQ:GHRS), and LB Pharmaceuticals (NASDAQ:LBRX).
GH001 cleared by FDA for U.S. clinical investigation, enabling U.S. subject enrollmentCompany to seek FDA alignment on global Phase 3 program replicating Phase 2b designPhase 3 initiation targeted for 2026 DUBLIN, Jan. 05, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (NASDAQ:GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on its Investigational New Drug Application (IND) for GH001. This clearance enables U.S. subject enrollment and progresses the company toward alignment of its development ac
DUBLIN, Jan. 02, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (NASDAQ:GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today reported that it will provide an update on the status of its Investigational New Drug Application (IND) for GH001 with the U.S. Food and Drug Administration (FDA) and its global pivotal Phase 3 program in treatment-resistant depression (TRD) on Monday, January 5, 2026, at 7.00 a.m. EST. About GH Research PLC GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
3 - GH Research PLC (0001855129) (Issuer)
3 - GH Research PLC (0001855129) (Issuer)
3 - GH Research PLC (0001855129) (Issuer)
3 - GH Research PLC (0001855129) (Issuer)
3 - GH Research PLC (0001855129) (Issuer)
3 - GH Research PLC (0001855129) (Issuer)
3 - GH Research PLC (0001855129) (Issuer)
3 - GH Research PLC (0001855129) (Issuer)
6-K - GH Research PLC (0001855129) (Filer)
6-K - GH Research PLC (0001855129) (Filer)
EFFECT - GH Research PLC (0001855129) (Filer)
6-K - GH Research PLC (0001855129) (Filer)
F-3 - GH Research PLC (0001855129) (Filer)
424B5 - GH Research PLC (0001855129) (Filer)
6-K - GH Research PLC (0001855129) (Filer)
6-K - GH Research PLC (0001855129) (Filer)
6-K - GH Research PLC (0001855129) (Filer)
6-K - GH Research PLC (0001855129) (Filer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Needham initiated coverage of GH Research PLC with a rating of Buy and set a new price target of $19.00
Cantor Fitzgerald resumed coverage of GH Research PLC with a rating of Overweight and set a new price target of $25.00
Guggenheim initiated coverage of GH Research PLC with a rating of Buy and set a new price target of $32.00
RBC Capital Mkts initiated coverage of GH Research PLC with a rating of Outperform and set a new price target of $31.00
Cantor Fitzgerald initiated coverage of GH Research PLC with a rating of Overweight and set a new price target of $14.00
H.C. Wainwright initiated coverage of GH Research PLC with a rating of Buy and set a new price target of $45.00
ROTH Capital initiated coverage of GH Research PLC with a rating of Buy and set a new price target of $66.00
Stifel initiated coverage of GH Research PLC with a rating of Buy
JMP Securities initiated coverage of GH Research PLC with a rating of Mkt Outperform and set a new price target of $35.00
Cowen & Co. initiated coverage of GH Research with a rating of Outperform
Live Leadership Updates
DUBLIN, Ireland, Sept. 03, 2024 (GLOBE NEWSWIRE) -- GH Research PLC (NASDAQ:GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced the promotion of Dr. Velichka "Villy" Valcheva, MD, MSc. to Chief Executive Officer of the Company. Dr. Valcheva succeeds PD Dr. med. Theis Terwey, co-founder of GH Research. Dr. Valcheva has more than 20 years of experience in various leadership roles in the pharmaceutical and biotech industries. Dr. Valcheva joined the company in August 2023 and has served as the Company's Chief Medical Officer since February 2024 having leadership responsibility, among other thin
DUBLIN, Ireland, Aug. 23, 2023 (GLOBE NEWSWIRE) -- GH Research PLC (NASDAQ:GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the second quarter ended June 30, 2023 and provided business updates. Second Quarter 2023 Financial Highlights Cash position Cash, cash equivalents, other financial assets and marketable securities were $238.1 million as of June 30, 2023, compared to cash, cash equivalents and marketable securities of $251.7 million as of December 31, 2022. Cash equivalents and other financial assets comprise money market funds. Marketable securities comprise inv
Live finance-specific insights
Primary endpoint met, GH001 led to an ultra-rapid anti-depressant effect with a significant placebo-adjusted MADRS reduction from baseline of -15.5 on Day 8 (p<0.0001)The majority of the patients treated with GH001 achieved remission with a 57.5% remission rate on Day 8 compared with 0% in the placebo group (p<0.0001)All other secondary endpoints were met with clinically and statistically significant improvements on Day 8, compared with placeboDuring the double-blind part, GH001 was well tolerated and no serious adverse events (SAE) were reported. There was no evidence of treatment-emergent suicidal ideation or behavior. As of January 22, 2025, no SAEs have been reported throughout the open
DUBLIN, Jan. 31, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (NASDAQ:GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced that it will host a conference call and live webcast on Monday, February 3, 2025, at 8.00 a.m. EST to provide an update on data from the randomized, double-blind, placebo-controlled Phase 2b trial of GH001 in treatment-resistant depression (TRD). To access the conference call, please register in advance here. A live webcast of the call will be available under "Events & Presentations" in the Investors section of GH Research PLC's website at ghres.com. About GH Research PLC GH
This live feed shows all institutional transactions in real time.
SC 13G/A - GH Research PLC (0001855129) (Subject)
SC 13G/A - GH Research PLC (0001855129) (Subject)
SC 13G - GH Research PLC (0001855129) (Subject)
SC 13G/A - GH Research PLC (0001855129) (Subject)
SC 13G/A - GH Research PLC (0001855129) (Subject)
SC 13G/A - GH Research PLC (0001855129) (Subject)
SC 13G - GH Research PLC (0001855129) (Subject)
SC 13G/A - GH Research PLC (0001855129) (Subject)
SC 13G/A - GH Research PLC (0001855129) (Subject)
SC 13G/A - GH Research PLC (0001855129) (Subject)